Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients

A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients

“…The specificities of the 2 assays are comparable, and high correlations exist between the immunoassay and HPLC results (19,20 ). Although immunoassays overestimate Tac concentrations by up to 20% because of concurrent measurement of metabolites, this methodology has proved feasible for assessing differences in Tac concentrations with respect to the CYP3A5 genotype (21 ).…”

Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography–tandem mass spectrometry

“…methods for monitoring tacrolimus levels [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25]. These methods can be divided into two categories, immunoassays, such as enzyme-linked immunosorbant assay (ELISA), microparticle enzyme immunoassay (MEIA) [9][10][11][12][13][14][15][16] and enzymemultiplied immunoassay technique (EMIT) [11,[17][18][19], and chemical methods, such as LC-MS or LC-MS/MS methods [15,16,[20][21][22]. Immunoassay methods are widely employed as routine therapeutic drug monitoring of tacrolimus for patients.…”

Évaluation du réactif tacrolimus Emit® 2000 (Dade Behring) et comparaison au réactif IMx® Tacrolimus II (Abbott) dans le suivi des transplantes hépatiques

“…Les études de répétabilité inférieure à 8 % et de reproductibilité inférieure à 12 % sont satisfaisantes et similaires à celles trouvées par d'autres auteurs [8]. La limite de détec-tion a été trouvée proche de celle annoncée par le fabricant.…”